H.C. Wainwright analyst Oren Livnat raised the firm’s price target on Xeris Biopharma (XERS) to $8 from $6.60 and keeps a Buy rating on the shares. The company’s first-time 2025 guidance for $255M-$275M in revenue is a “surprising” 11% above estimates and up 30% year-over-year at the midpoint, the analyst tells investors in a research note. The firm continues to view Xeris Biopharma as a top pick for 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue